Health

Children with TB cannot wait as MSF urges countries to roll out shorter treatment

New study supports introduction of four-month treatment for children with non-severe TB in routine healthcare settings

RIO DE JANEIRO, November 17, 2026 – Médecins Sans Frontières [ MSF ] has urged governments to accelerate the roll-out of shorter tuberculosis [TB] treatment for children, following new study findings showing that the World Health Organization [WHO]-recommended four-month regimen can be successfully implemented in routine primary healthcare settings.

The study, conducted in Uganda and the Philippines, was presented at the Union World Conference on Lung Health in Rio de Janeiro, Brazil. It found that the shorter treatment regimen for children with non-severe TB is feasible in routine healthcare settings and can achieve high treatment success rates.

MSF is calling on governments, donors and global health partners to move beyond adopting the policy and accelerate its implementation, while strengthening TB diagnosis, prevention and care for all affected children.

The findings show that up to 74 percent of children with TB overall, and up to 89 percent of those treated in primary healthcare settings, are eligible for the shorter regimen.

The four-month treatment offers a more patient-centred approach by reducing the treatment burden on children, their families and healthcare systems.

TB remains the world’s deadliest infectious disease, with children among those most affected. According to the WHO’s 2026 Global TB Report, half of children under five who developed TB in 2025 were missed by health systems and did not receive treatment, a situation that has remained largely unchanged in recent years.

“Every three minutes, a child dies of TB. We cannot keep leaving children behind when effective medical tools are already within reach, including reducing treatment duration for children with non-severe TB from six months to four months,” said Dr Ana Paula Cavalheiro, Leader of MSF’s Global TB Platform.

“It is high time governments and donors stepped up to ensure that children are diagnosed early and receive the best possible treatment and care, no matter where they live,” she added.

Despite the WHO recommending the four-month regimen in 2022, its uptake has remained slow in many countries with a high TB burden.

One of the major challenges has been identifying children with non-severe TB who can safely benefit from the shorter treatment. This requires clinical assessment and, where available, chest X-ray [CXR] examinations.

However, MSF says its latest findings provide practical evidence that these challenges can be addressed in routine healthcare programmes.

“The four-month treatment regimen for children with non-severe, drug-susceptible TB uses the same medicines, including child-friendly formulations, but substantially reduces the burden on children and caregivers,” said Valentina Carnimeo, Principal Investigator of the MSF multi-country TB study.

“Fewer months of treatment means fewer clinic visits, less disruption to family life, lower costs for caregivers and health systems, and fewer days exposed to potential adverse effects.

“The evidence is clear: countries can confidently implement this regimen in routine care, and children should not have to wait longer to benefit from it,” she added.

The prospective study involved 214 children receiving care at health facilities in Uganda and the Philippines. Nearly three-quarters [74 percent] were found eligible for the four-month regimen at the start of treatment.

Treatment outcomes were positive, with 95 percent of the children successfully completing treatment.

Healthcare workers and caregivers welcomed the shorter regimen, citing fewer clinic visits and reduced pressure on families.

However, the study identified several challenges to wider implementation, including limited access to chest X-ray services, inadequate training for healthcare workers and high staff turnover.

“Our experience of implementing the four-month TB treatment regimen for children shows that it can be successfully introduced into routine care, leaving no reason to delay its wider roll-out,” said Dr Maria Namulwana, Study Coordinator at MSF/Epicentre Uganda.

“But to make this a reality for more children, governments must go beyond updating guidelines and invest in training healthcare workers, strengthening diagnostic services, ensuring access to child-friendly medicines and supporting families throughout treatment,” she added.

Non-severe tuberculosis is a milder form of tuberculosis where the disease is limited and has not caused extensive damage to the lungs or spread widely in the body.

Drug-susceptible tuberculosis is a form of tuberculosis that responds to the standard first line medications and is not resistant to key drugs.

The WHO-recommended four-month regimen for children with non-severe, drug-susceptible TB consists of two months of isoniazid, rifampicin and pyrazinamide, with or without ethambutol, followed by two months of isoniazid and rifampicin [2HRZ[E]/2HR]. It uses the same medicines as the standard six-month regimen [2HRZ[E]/4HR], including child-friendly dispersible tablets.

MSF has been working to improve TB care for children in 12 countries, through its Test, Avoid and Cure TB in Children (TACTiC) initiative, by putting the latest WHO recommendations into practice and generating evidence to support their wider adoption.

https://thecooperator.news/new-africa-cdc-global-fund-partnership-to-strengthen-africas-health-systems/

Buy your copy of thecooperator magazine from one of our country-wide vending points or an e-copy on emag.thecooperator.news

Related Articles

Back to top button